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The identification of IgD in normal human serum  (1) and its subsequent discovery 
of on  the surface of most  primate  (2-5)  and  rodent  (6-9)  B  lymphocytes generated 
questions regarding the function of this Ig isotype. In studying this problem, Pernis 
(10) injected rhesus monkeys with a rabbit antiserum specific for human IgD (RailS), l 
which cross-reacts with monkey IgD. These monkeys developed substantial increases 
in serum IgM and IgG levels, which were entirely accounted for by antibodies specific 
for constituents of rabbit serum. These experiments suggested that anti-IgD can have 
an adjuvant effect on the humoral immune response to simultaneously injected foreign 
antigens (10), but is not a  polyclonal activator of B  lymphocyte terminal differentia- 
tion.  Pernis's interpretation has been supported by other studies that  demonstrated 
that  the injection of an  IgG fraction of Rail8  or affinity-purified Rail8  into rhesus 
monkeys  could  considerably enhance  the  IgG  response  to  a  subsequently  injected 
antigen, but did not lead to a polyelonal increase in serum IgM or IgG levels (11,  12). 
The  adaptation  of  this  model  to  the  mouse  has  been  made  possible  by  the 
production  of hybridoma-derived  monoclonal  anti-mouse  8-chain  antibodies  (13). 
One such antibody is an IgG~ of the b  allotype secreted by hybridoma  10-4.22  (14) 
that has specificity for the Fc fragment of mouse 8-chain of the a  allotype (4.22aM~) 
(15). We report here the effects of 4.22aM~  on the IgM and IgG anti-2,4,6-trinitro- 
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phenyl (TNP) response to TNP-conjugated sheep erythrocytes (SRBC)  (TNP-SRBC) 
and  TNP-conjugated  aminoethylcarbamylmethylated  (AECM)-Ficoll  (TNP-FicoI1). 
Our  results  indicate  that  although  4.22aM8 a  by  itself  stimulates  neither  B  cell 
proliferation  nor terminal  differentiation  when  injected  into  BALB/c  mice,  it  sub- 
stantially enhances the IgG anti-TNP response and modestly enhances the IgM anti- 
TNP  response  to subsequently  injected  TNP-Ficoll  or TNP-SRBC.  We have  found 
that the degree of enhancement of the IgG anti-TNP response is highly dependent on 
the dose of TNP-SRBC or TNP-Ficoll used and on the time interval between injection 
of 4.22aMb  ~  and  antigen,  and  that  even  in  the  case  of the  T-independent  antigen 
TNP-Ficoll this enhancement appears to be T  lymphocyte dependent. 
Materials  and Methods 
Animals.  Male BALB/c mice were obtained from Microbiological Associates,  Walkersville, 
Md. Male athymic (nu/nu) mice and their phenotypieally normal (+/+ and nu/+) littermates 
were obtained from the Small Animal Section, Division of Research Services, National Institutes 
of Health (NIH), Bethesda, Md. Male C.B20 mice, which are congenie to BALB/c but possess 
the Igh genes of C57BL/Ka, were bred from mice originally obtained from Dr. Michael Potter, 
NIH. All mice were at least 8 wk old when used. 
Antigens.  TNP6~ECM  Ficoll  was purchased  from  Biosearch,  St.  Raphael,  Calif.  TNP- 
SRBC with a high hapten density were prepared as previously described (16). 
Antibodies.  The  preparation  of the  following  antibodies  has  been  described  elsewhere: 
isotype-specific affinity purified rabbit anti-mouse y-chain (RaMT)  and rabbit  anti-mouse/t- 
chain  (RAM/0  (17),  affinity-purified rabbit  anti-keyhole limpet  hemocyanin (RaKLH), and 
4.22aM~  (18). The monoelonal IgG2a secreted by the plasmacytoma CBPC-101, which does 
not bind to mouse cells, was purified from the ascites fluid of C.B20 mice that bore this tumor 
by elution  from protein  A-Sepharose.  Both  4.22aM~  and  CBPC-101  bear  the  b  allotypic 
determinanis  characteristics of C57BL/6 IgG~ immunoglobulins. A  rabbit  antibody against 
idiotypic determinants  of 4.22aM~  (Ra4.22Id)  was prepared  by immunizing a  rabbit  with 
4.22aM~, absorbing the antiserum with normal BALB/c serum-Sepharose, and immunospe- 
cifically purifying the absorbed antiserum on a column of 4.22aM~-Sepharose.  The identifi- 
cation and purification of two mouse IgDx plasmaeytoma proteins, TEPC-1017 and TEPC- 
1033,  and  the  production  of an  affinity-purified  isotype-specific rabbit  anti-mouse  8-chain 
(RAMS) antibody will be described in detail in a separate paper (F. Finkelman, S. Kessler,  F. 
Mushinski, and M. Potter. Manuscript in preparation.).  RaM/t and RAM,/were labeled with 
Na[125I] (Amersham Corp., Arlington Heights, Ill.)  by the chloramine T  technique (19);  and 
4.22aM~ and F(ab')2 fragments of affinity-purified RAMS, RaM/t, RaMy, and RaKLH were 
labeled with fluorescein isothiocyanate (FITC) to molar fluorescein:protein ratios of from 2:1 
to 5:1 as previously described (20). 
Measurement of Serum Immunoglobulin Levels.  Serum  IgG and  IgM were quantitated  by the 
radial immunodiffusion technique. IgG1, IgG2a, and IgG2b levels in  10-/tl serum samples were 
measured with radial immunodiffusion plates purchased from Meloy Laboratories Inc., (Spring- 
field, Va.). In other experiments, radial immunodiffusion plates prepared with RaMy that was 
sequentially affinity purified on columns of mouse IgGx and IgGza plasmacytoma proteins that 
were  bound  to  Sepharose  were  used  to  measure  total  IgG  levels.  Serum  IgM  levels  were 
measured with radial immunodiffusion plates prepared with isotype-specific RaM/t antiserum. 
Quantitation of Immunoglobulin on Mouse Spleen Cells.  Single cell  suspensions  were  prepared 
from spleens of BALB/c mice that had been injected with 200/tg of CBPC-101 or 4.22aM8  a, 
treated  with erythrocyte lysing buffer, and suspended  in Hanks' balanced  salt  solution that 
contained  10% fetal bovine serum and 0.2% NaN3 (HFA). Aliquots of 2 ×  106 spleen cells in 
100 /tl  of HFA were  stained  for  30  min  at  0°C  with  0.5  /tg  of FITC-labeled  CBPC-101, 
4.22aM~, or affinity-purified F(ab')2 fragments of RAMS, RaM/t, RAM-/, or RaKLH; washed; 
and analyzed for surface fluorescence with a fluorescence-activated cell sorter (FACS II; Becton, 
Dickinson FACS Systems, Mountain View, Calif.)  as previously described (20, 21). 
Measurement of Spleen  Cell  Proliferation.  Spleen  cell  suspensions  were  prepared  from  mice FINKELMAN ET  AL.  495 
injected with 4.22aM~ or CBPC-101. Triplicate cultures of 5 ×  105 cells each were incubated 
in flat-bottomed wells of microtiter plates in 0.2 ml of modified Mishell-Dutton medium with 
1 pCi of [3H]thymidine/well for 4  or 24  h.  Cells were harvested with a  Mash  II harvester 
(Microbiological Associates) and  [aH]thymidine incorporation was analyzed by scintillation 
spectroscopy. 
Titration of Anti-TNP Levels in Mouse Sera.  IgG and IgM anti-TNP antibody levels in mice 
immunized with TNP-SRBC  or TNP-Ficoll were titered with a  solid-phase microtiter plate 
radioimmunoassay (22).  TNP-Ficoll coated U-bottomed Wells in Flexvinyl microtiter plates 
(Cooke Engineering Co., Alexandria, Va.) were washed with 0.1% ovalbumin (OVA) in Tris. 
Negative control plates were prepared without TNP-FicolI. Positiue control plates were prepared 
by exposing wells to 100 pg/ml of IgG1, IgG2a, IgG3, or IgM instead of TNP-Ficoll. Individual 
sera  were  diluted  to  1:40,  1:160,  1:640,  and  1:2,560  in  OVA-Tris  buffer.  Duplicate  25-#1 
aliquots of each serum dilution were pipetted into TNP-Ficoll-coated wells and incubated for 
30 min at room temperature, after which, wells were washed, refilled with 25 pl of a~SI-RaMT 
or 125I-RaMp  (106 cpm/ml) in OVA-Tris buffer, incubated for 1 h at room temperature, and 
washed  again. Individual wells were cut  from  plates and  counted  in  a  gamma counter.  In 
4  125  preliminary experiments, ~8 ×  10  cpm of  I-RaM~ bound to IgM-coated wells, and ~6 × 
4  4  4  125  10 , ~4 ×  10 , and ~ 1.5 ×  10  cpm of  I-RaMy bound to IgGl-, IgG2a-, and IgGa-coated wells, 
respectively. Less than  10  a cpm of either reagent bound to wells coated either with OVA only 
or with TNP-Ficoll and OVA but which were not exposed to mouse serum. Less than  103 cpm 
of L25I-RaMp bound to mouse IgG-coated wells and, similarly, <103 cpm of 12SI-RaMT bound 
to mouse IgM-coated wells. In general, TNP-Ficoll-coated wells exposed to an immune mouse 
serum bound  5-10 times as much  125I-RaMp  and  10-20 times as much  x25I-RaM3, as OVA- 
coated wells exposed to the same dilution of the same serum. Serum titers were defined as the 
reciprocal of the serum dilution which was calculated by linear regression analysis of logarithms 
of serum dilutions to bind a  given number of cpm of 125I-RaMbt or 12~I-RaMy  (titer point). 
Titer points were chosen to allow for titration of all serum samples analyzed without extrapo- 
lation, and, when  possible, to intersect titration curves of individual sera plotted on  log-log 
paper at the steepest part of their slopes. Serum titers obtained this way provide only for relative 
measurement of serum antibody levels of simultaneously analyzed sera. 
Results 
Effects on  Cell Surface  lmmunoglobuin.  1,  3,  5, or  7  d  after  10-wk-old BALB/c mice 
were injected intravenously with 200 #g of 4.22aM~ or CBPC-101,  their spleen cells 
were obtained and stained with FITC-labeled RAMS, RaKLH,  4.22aM~, CBPC-101, 
RaM/~, or RaM T. Fig.  1 shows the fluorescence profiles obtained by FACS II analysis 
of cells taken 3 and 7 d  after in vivo injection of 4.22aM~ or CBPC-101  and stained 
with FITC-labeled RAMS, RaKLH,  or RaMp.  3  d  after the 4.22aM8 a injection, the 
intensity  of spleen  cell  staining  for  surface  IgD  (sIgD)  is  greatly  diminished  and 
approaches the low value of cells stained nonspecifically with FITC-RaKLH.  Similar 
profiles were obtained from cells derived from mice given 4.22aM~  24 h  previously 
that  were  stained  with  either  FITC-RaM8  or  FITC-4.22aM8  a.  Cells  from  mice 
injected with 4.22aM~  stained no more brightly with  FITC-RaMT, which  binds to 
4.22aMb  ~,  than  did  cells  from  CBPC-101-injected  mice  (data  not  shown).  Thus, 
decreased  FITC-RaM8  staining  of cells from  4.22aM~-treated  mice  is  a  result  of 
modulation ofsIgD rather than blocking of S-chain determinants by 4.22aM~. Spleen 
cells from  mice  injected 5  or  7  d  previously with  4.22aMb  ~  had  considerably more 
sIgD than did cells from spleens removed  1 or 3  d  after the 4.22aM~  injection, but 
considerably less than did spleen cells from control mice. Fig.  1 also shows that 3 and 
7 d after in vivo 4.22aM~ treatment, the frequency of spleen cells that bore detectable 
surface IgM  (sIgM) was diminished:  28-29%  as compared to 44%  in  mice that  had 
received CBPC-101.  Because the total number of cells that bore cell surface I-region 496  ANTI-8-CHAIN-ANTIBODY-ENHANCED  MURINE ANTIBODY SECRETION 
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FxG.  1.  Two groups of six BALB/c mice were injected with 200 p.g of CBPC-101 (--) or 4.22aM~  a 
(- - -)/mouse. Three mice from each group were killed 3 d later and their spleen cells were pooled 
and  stained  with  FITC-RaM~  (A)  or  FITC-RaM/t  (B). These ceils were then  analyzed  for 
fluorescence intensity with a FACS. To provide a measure of nonspecific  staining, spleen cells from 
CBPC-101-treated mice were stained with FITC-RaKLH  (...)  and similarly analyzed. In the 
fluorescence profiles shown, the fluorescence intensity of stained cells increases along the abscissa, 
while the ordinate depicts the number of cells at each level of fluorescence intensity. (C) and (D) 
show fluorescence  profiles of spleen cells obtained from mice injected with 4.22aM~ or CBPC-10! 
7 d before killing and stained with FITC-RaM8 (C) or FITC-RaM/t (D) as well as with FITC- 
RaKLH. 
associated (Ia) antigen or a  receptor for the third component of complement was not 
diminished by this treatment, (data not shown) this result suggests that some B cells 
lose slgM as well as slgD after treatment with 4.22aM~. 
Persistence  of Injected 4.22aM8 a.  Sera from six mice injected with 200 or 800 ~g of 
4.22aMb  ~ were obtained 5 and 7 d after the 4.22aM8" injection and were analyzed for 
their  ability to  form  a  precipitin line with  Ra4.22Id  (100  /.tg/ml)  in Ouchterlony 
plates. Sera from all six mice injected 5 d  or 7 d  previously with 800 #g of 4.22aM8  a, 
sera from all six mice injected 5 d  previously with 200 ~g of 4.22aM~, and three of 
six sera from mice injected 7 d previously with 200 ~g of4.22aMb  ~ generated precipitin 
lines with Ra4.22Id antibody. 
Effects  of In  Vivo  4.22aM8 ~ on  the Hurnoral  lmmune  Response  to  TNP-Ficoll and  TNP- 
SRBC.  BALB/c mice were injected intravenously  with 100 ~tg of 4.22aM~ or CBPC- 
101 and were given 0.2 ml of 10% TNP-SRBC intravenously or 100 ~g of TNP-Ficoll 
intraperitoneally 24 h  later.  Serum samples obtained before and 5,  7,  10,  and  13  d 
after immunization were assayed for their IgG and IgM anti-TNP titers by radioim- 
munoassay. Fig.  2  shows log-log plots of counts per minute of 125I-RaM~t  bound to 
serial  fourfold  dilutions of sera  obtained 5  d  after TNP-SRBC  immunization and 
similar plots of counts per minute of 125I-RaMy bound to dilutions of sera drawn 7 d 
postimmunization. Each point represents the geometric mean of the counts per minute "6 
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Fro.  2.  Effect of 4.22aM~ on the anti-TNP response in TNP-SRBC-immunized mice. Two groups 
of six BALB/c mice were given 100 #g of 4.22aM~ (O) or CBPC- 101 (A)/mouse 1 d before injection 
with 0.2 ml of 10% TNP-SRBC. Sera obtained 5 d after immunization were assayed for IgM anti- 
TNP antibody (A), whereas sera obtained 7 d after immunization were assayed for IgG anti-TNP 
antibody (B).  40-,  160, 640-,  and 2,560-fold  dilutions of individual sera were analyzed by solid- 
phase microtiter plate radioimmunoassay for the counts per minute of 126I-labeled RaM/~ or RaM7 
that were bound to mouse antibody that was adherent to TNP-Ficoll-coated  wells.  Each point 
represents the geometric mean ×/+ SE of counts per minute of 1251-antibody bound by the specified 
dilution of sera from six mice. 
TABLE  I 
Effects of 4.22aM~ a, CBPC-IOI, or No Antibody on the Primary Anti-TNP 
Response to TNP-SRBC in BALB/c Mice 
Serum titer* 
Antibody injected 
lgM (day 5)  IgG (day 7) 
None  130 (1.51)  133 (1.20) 
CBPC-101  328 (1.11)  171  (1.28) 
4.22aM8"  679 (1.20)  1,560 (1.23) 
Three groups of six BALB/c mice were given no antibody, 200 #g of CBPC- 
101, or 200 p.g of 4.22aM~/mouse, followed by immunization with 0.2 ml of 
10% TNP-SRBC  1 d later. 
* Geometric mean. Standard error in parentheses. 
of ~25I-RaM#  or RaMy bound by a  given dilution of serum from 6 mice.  Sera from 
mice that  received  4.22aM~'  had  approximately  five times  as much IgG  anti-TNP 
antibody  and  approximately  twice  as  much  IgM  anti-TNP  antibody  as mice  that 
received  CBPC-101.  It  should  be  noted  that  similar  relative  differences  in  titer 
between sera from 4.22aM~-  and CBPC-101-treated  mice would be calculated if the 
IgG anti-TNP titer point were chosen anywhere between 4  ×  103 and 4.5  ×  10  4 cpm 
and if the IgM  anti-TNP  titer point were chosen anywhere between 4  ×  10 a and 3 
×  104 cpm. 
To assure  that  the enhancement seen  in 4.22aMY-treated  mice did  not  actually 
reflect  suppression  by  the  control  immunoglobulin,  CBPC-101,  three  groups  of six 
mice  each  were  injected  with  200  #g  of  CBPC-101,  200  #g  of  4.22aMY,  or  no 
antibody,  followed by immunization  24 h  later with TNP-SRBC.  As shown  in Table 
I,  5-d postimmunization  sera from  mice given 4.22aM~  had  a  geometric  mean  IgM 498  ANTI-8-CHAIN-ANTIBODY-ENHANCED  MURINE  ANTIBODY  SECRETION 
TaBcE  II 
Effects of 4.22aM6 a on Primary Anti-TNP Response to TNP-SRBC in 
C. B20 Mice 
Antibody injected 
Serum titer* 
IgM (day 5)  IgG (day 7) 
4.22aMb  ~  175 (1.29)  374 (1.43) 
CBPC-101  149 (I.23)  399 (1.28) 
Two groups of six C.B20 mice were given 200 #g of 4.22aM~ or CBPC-101/ 
mouse, followed by immunization with 0.2 ml of 10% TNP-SRBC  1 d  later. 
* Geometric mean. Standard error in parentheses. 
anti-TNP titer approximately twice that of mice given CBPC-101 and approximately 
five times  that  of mice  given  no  antibody;  whereas  sera obtained  from  4.22aM8  ~o 
treated  mice  7  d  after immunization  contained  approximately ninefold  more  IgG 
anti-TNP antibody than  mice given CBPC-101  or no antibody.  In another experi- 
ment, the ability of 4.22aM~  to enhance anti-TNP antibody production  by C.B20 
mice immunized with TNP-SRBC was analyzed. Because 4.22aM~ binds IgD of the 
a  allotype (found in BALB/c mice)  but  not of the b  allotype (found in C57BL/Ka 
mice) and C.B20 mice are a  BALB/c congenic strain that has C57BL/Ka Ig heavy- 
chain genes, 4.22aM~ would be expected to enhance anti-TNP antibody production 
in these mice if the enhancing factor were something other than anti-8-chain activity. 
C.B20  mice treated  with  4.22aM~  made no more IgM or IgG anti-TNP antibody 
than did mice treated with CBPC-101  (Table II). 
We next studied  the kinetics of anti-8-chain  enhancement  of anti-TNP antibody 
responses  in  mice immunized with  TNP-Ficoll  or TNP-SRBC  24  h  after injection 
with 4.22aM~  or CBPC-101.  These experiments demonstrated  that  IgM anti-TNP 
titers were higher on day 5 than on day 7, whereas IgG titers were higher on day 7 
than on days 5,  10, or 13 (data not shown). At all times studied, IgG anti-TNP titers 
in the mice that received 4.22aM~  exceeded those of CBPC-101 recipients by a factor 
of approximately five, whereas the enhancement of IgM anti-TNP antibody produc- 
tion by 4.22aMb  TM  was approximately twofold. 
We  next  examined  the  effects of varying the  doses of antigen  and  4.22aM~  on 
anti-8-chain enhancement of anti-TNP antibody responses. Mice were injected with 
25,  100, or 800/lg of 4.22aM~ or CBPC-101  24 h before TNP-SRBC immunization. 
5- and 7-d sera were titered for IgM and IgG anti-TNP antibody, respectively. Both 
IgG  and  IgM  titers  were  higher  in  sera  obtained  from  mice  that  had  received 
4.22aM~  instead of CBPC-101  at all three antibody doses tested  (data not shown), 
and  the  variation  observed with  different  antibody  doses was  not  substantial.  En- 
hancement of the IgG anti-TNP response by 4.22aM~  does appear, however, to be 
highly dependent  upon the dose of antigen administered.  As is seen in Fig.  3A, the 
IgG anti-TNP response decreased with decreasing amounts of TNP-SRBC and this 
effect was particularly pronounced in mice that had received 4.22aM~  rather than 
CBPC-101.  Mice given 4.22aMb  ~  before immunization with 0.2 ml of 10,  1, or 0.1% 
TNP-SRBC made 9.2-, 2.5-, and  1.1-fold more IgG anti-TNP antibody, respectively, 
than  did mice immunized with  the same quantity of antigen  after having received 
CBPC-101.  Similarly,  the  IgG  anti-TNP  response  to  100  ~g  of  TNP-Ficoll  was 
enhanced  more by 4.22aM~  (9.4-fold)  than  the response to  10/.tg or  1 /~g of TNP- FINKELMAN ET AL.  499 
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FIG.  3.  Effect of antigen  dose on 4.22aM6  a enhancement of the  anti-TNP humoral  immune 
response. Two groups of 36 BALB/c mice were given 200 #g of 4.22aM~' (--) or CBPC-101 (- - -) 
per mouse. 1 d later, six mice in each group were immunized with l, 10, or 100 #g of TNP-Ficoll 
(A) or 0.2 ml of 0.1, 1, or 10% TNP-SRBC (O)/mouse. Sera obtained 5 and 7 d after immunization 
were titered for IgM anti-TNP levels (A) and IgG anti-TNP levels (B), respectively. Each point 
represents the geometric mean ×/+ SE of the titers of six individual sera. 
Ficoll  (5.8-fold  or  1.9-fold,  respectively).  Although  a  similar  trend  was  seen  in 
4.22aM~  enhancement  of  the  IgM  anti-TNP  response  (Fig.  3B)  the  effects  of 
variation of antigen dose on enhancement of IgM anti-TNP was much less striking 
than that seen on IgG anti-TNP levels. The lack of any enhancement by 4.22aM~ of 
either the IgG or IgM anti-TNP response of 0.2% TNP-SRBC is particularly mean- 
ingful, as it indicates that 4.22aM~ in the absence of other antigens does not induce 
any  detectable  anti-TNP  humoral  immune  response  (i.e.,  it  is  not  a  polyclonal 
activator). 
The effect of varying the interval between administration of 4.22aM~ or CBPC- 
101  and antigen was studied in experiments in which sera were obtained 5 and 7 d 
after TNP-SRBC administration for determination of IgM and IgG anti-TNP titers, 
respectively. Administration of 4.22aM~  1 d  before antigen enhanced the IgG anti- 
TNP response more than when 4.22aM~ was given simultaneously with or 3 d before 
antigen (Fig. 4). Furthermore, no significant 4.22aM6" enhancement was seen when 
4.22aM~ was given 7 or 14 d before antigen or 3 d after antigen. The effect of varying 
the interval between 4.22aM~ and TNP-SRBC administration on the IgM anti-TNP 
response was less striking. 
The possibility that T  lymphocytes might play a  role in 4.22aM6  a enhancement of 
humoral immune responses was studied by giving 200 #g of 4.22aM8  a or CBPC-101 1,00C  1,000 
lOC 
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INTERVAL  (DAYS) BETWEEN ANTIBODY  INTERVAL (DAYS) BETWEEN  ANTIBODY 
AND TNP--SRBC INJECTION  AND TNP-SRBC  INJECTION 
Fie.  4.  Effect of varying the interval  between administration of 4.22aMb  ~  and TNP-SRBC on 
4.22aM~ enhancement of the humoral anti-TNP response. Groups of six BALB/c mice were given 
200 #g of CBPC-101  (- - -) or 4.22aM~ (--)/mouse 14, 7, 3, or 1 d before immunization with 0.2 
ml of 10% TNP-SRBC or were given CBPC-101  or 4.22aM~ simultaneously with, or 3 d  after, 
TNP-SRBC immunization. IgM and IgG anti-TNP titers were obtained for sera drawn 5 d (A) and 
7 d (B) after immunization, respectively. 
TABLE  III 
Effect of 4.22aM8 ~ on nu/nu and Normal Anti-TNP Responses to TNP-SRBC and  TNP-Ficoll 
Titer* 
Experi-  Mice  Antibody  IgM  IgG 
ment 
TNP-  TNP-  TNP-  TNP- 
SRBC  Ficoll  SRBC  Ficoll 
Normal¢  4.22aMb  ~  538 (1.26)  499 (1.62)  949 (1.62)  1,510 (1.35) 
CBPC-101  355 (1.43)  259 (1.32)  144 (1.55)  275 (1.59) 
nu/nu  4.22aM~  0  466 (1.19)  0  489 (1.33) 
CB~-I01  0  636 (1.27)  0  407 (1.64) 
2  nu/nu  4.22aM~  209 (1.29) 
CBPC- 101  207 (1.10) 
In experiment 1, groups of six athymic (nu/nu)  mice or their phenotypically normal littermates were 
given 200 #g of CBPC-101 or 4.22aM~/mouse 1 d before immunization with 100 #g of TNP-Ficoll or 0.2 
ml of 10% TNP-SRBC. Sera obtained 5 and 7 d after immunization were titered for IgM and IgG anti- 
TNP antibody levels, respectively.  Experiment 2 is a partial repeat of experiment 1, with only athymic 
mice and TNP-Ficoll. 
* Geometric mean. Standard error in parentheses. 
:~ nu/+ or +/+ littermates of nu/nu mice. 
to congenitally athymic  (nu/nu)  mice or their phenotypically normal  (nu/+  and +/ 
+)  littermates, and  immunizing  them  with 0.2  ml of 10%  TNP-SRBC  or  100  #g of 
TNP-Ficoll 24 h  later. As expected, the phenotypically normal mice generated strong 
IgM  and  IgG  anti-TNP  antibody  responses to  both  TNP-SRBC  and  TNP-FicolI. 
These  IgM  responses  were  enhanced  slightly,  whereas  these  IgG  responses  were FINKELMAN ET  AL.  501 
enhanced considerably by 4.22aM~  (Table III). Also as expected, nu/nu mice made 
no detectable anti-TNP antibody in response to TNP-SRBC, but did produce IgM 
and IgG anti-TNP antibodies when immunized with TNP-FicoI1, the titer of which, 
in fact, exceeded that produced by their normal littermates. However, in this, as in a 
subsequent experiment (Table III, experiment 2), no enhancement by 4.22aM~ was 
seen. These findings indicate that directly or indirectly, T  cells play a role in anti-IgD 
enhancement of in vivo humoral responses. 
Effect  of 4.22aM8 ~ on  Serum Immunoglobulin  Levels  and  Spleen  Cell Proliferation.  To 
determine if the enhanced antibody responses induced by 4.22aM~ were accompanied 
by an  increase in serum  immunoglobulin,  two groups of six mice were each given 
either 200 ttg of 4.22aM~ or CBPC-101 24 h before immunization with TNP-SRBC. 
Sera obtained 5 d  after immunization were analyzed by radial immunodiffusion for 
IgM and IgC_~, whereas  10-d sera were analyzed for IgGx and IgG2b. Mice injected 
with 4.22aM~ showed a more substantial rise in serum IgGx levels (+79 4- 13%) than 
mice  injected with  CBPC-101  (+22  -4-  10%);  changes  in  other isotype levels were 
comparable for both groups. In a  second experiment in which mice were given 200 
#g  of either  4.22aM~  or  CBPC-101  without  subsequent  antigenic  challenge,  no 
substantial  differences were seen in IgM or total IgG serum levels between the two 
groups. These data are consistent with our finding that 4.22aM~  does not enhance 
anti-TNP antibody production stimulated by low doses of TNP-SRBC  (i.e., anti-8- 
chain by itself has little or no activity as a polyclonal activator of antibody secretion). 
Spleen cells from mice given either 4.22aM6  ~ or CBPC-101  1, 3, 5, or 7 d  before 
were analyzed for their ability to incorporate [3H]thymidine during 4- and  24-h in 
vitro incubations. 4.22aM~' had no effect on spleen cell [3H]thymidine incorporation 
1, 3, and 5 d after injection and a twofold stimulatory effect 7 d  after injection. In a 
second experiment, even this slight stimulatory effect at day 7 was not seen. 
As another measure of the effect of 4.22aM~  on spleen cell proliferation, splenic 
fragments from mice given 4.22aM~ or CBPC-101 3 or 7 d before killing were fixed, 
sectioned, stained  with  hematoxalin  and  eosin,  and  examined  microscopically for 
mitotic figures. Less than  1% of splenic lymphoid follicle cells from either 4.22aM~- 
or CBPC-101-treated mice showed mitotic figures. 
Discussion 
The intravenous administration of anti-8-chain antibody removes almost all sIgD 
from mouse splenic B lymphocytes but leaves most sIgM on the majority of these cells 
intact. When antigen is given simultaneously, or  1 day after, anti-8-chain antibody, 
a  marked enhancement of antigen-specific IgG responses and  a  smaller increase in 
IgM responses are observed. This enhancement occurs in the absence of detectable 
anti-8-chain-stimulated polyclonal splenic B cell proliferation or terminal differentia- 
tion. These data are similar to previous studies of the effects of anti-8-chain on specific 
antibody responses in the rhesus monkey and rat  (10-12, 23, 24). Our results differ, 
however, from experiments by Dresser and Parkhouse (25), which suggested that anti- 
mouse  8-chain  antisera  inhibit  the  response  to  simultaneously,  or  subsequently, 
injected antigens. These experiments were unlike ours in that anti-SRBC rather than 
anti-TNP  antibody responses were examined, a  conventional rabbit  anti-mouse  8- 
chain antiserum was used instead ofa monoclonal mouse anti-mouse 8-chain antibody, 
and splenic plaque-forming cells rather than serum antibody levels were measured. In 502  ANTI-8-CHAIN-ANTIBODY-ENHANCED  MURINE ANTIBODY SECRETION 
preliminary experiments, our affinity-purified RaM8 antibody enhances IgG responses 
as well as or better than 4.22aM~ and does not suppress anti-TNP responses at doses 
varying from 6/xg to 2 mg. In addition, both 4.22aM~  a and RaM6 can enhance the 
IgG anti-SRBC response of mice immunized with TNP-SRBC  1 d  after treatment. 
Furthermore, the numbers of direct and indirect anti-SRBC plaque-forming cells are 
substantially enhanced by simultaneous administration of anti-8-chain antibody with 
SRBC (26). 
In  addition  to establishing that  anti-8-chain  antibody has an  adjuvant  effect on 
specific antibody production to TNP-Ficoll and TNP-SRBC, our data indicate that 
this adjuvant effect is not observed when suboptimal, but immunogenic, antigen doses 
are used. Furthermore, this adjuvant effect is observable in nu/+ but not nu/nu mice 
and, hence, appears to be T  cell dependent. The T  cell dependence of anti-8-chain 
antibody enhancement  of the  TNP-Ficoll response is  somewhat  surprising,  as  this 
antigen is widely thought to be T  independent and elicits a strong humoral immune 
response in nu/nu mice (27). However, recent studies by Kettman and Dodd (28) and 
Mond et al. (29) indicate that T  cell help is required for an optimal in vitro antibody 
response to TNP-Ficoll by B cells from normal mice. 
To  be  consistent  with  our  data,  models  of anti-8-chain  antibody  enhancement 
should  account  for:  (a)  the  requirement  for T  cell help,  (b)  the requirement  for a 
relatively high antigen dose, and (c) the wide range of anti-8-chain antibody concen- 
trations  that  produce  enhancement.  We  feel  that  these  observations  can  best  be 
explained within the confines of the two-signal theory of B cell stimulation;  that is, 
that B lymphocytes are optimally stimulated to differentiate into antibody-secreting 
cells by the triggering of both sIg receptors and other receptors specific for T  helper 
substances  and/or polyclonal activators (30).  Anti-8-chain  antibody could have an 
adjuvant effect on antigen-induced B lymphocyte terminal differentiation by increas- 
ing the amount or effect ofT cell help on B cells, by interfering with T cell suppression 
or T  cell dependent anti-idiotype suppression of B cells, or by changing the quantity 
and quality of the binding of ligand  to B cell sIg. These proposed effects of anti-8- 
chain antibody upon a humoral immune response are not mutually exclusive, but, for 
convenience, can be expressed as three separate models. The first model proposes that 
T  cells would respond to 4.22aM~ by generating helper factors specific for 4.22aM8  a 
which  would  be  focused onto B  cells polyclonally by binding  to 4.22aM~  that  is 
associated with sIgD. However, our failure to detect 4.22aM~ associated with spleen 
cells  by  sensitive  immunofluorescence  techniques  decreases  the  likelihood  of this 
hypothesis. 
A second model notes that anti-TNP antibody responses are limited by antibodies 
or suppressor substances specific for idiotypic determinants on anti-TNP antibodies 
(24). Because the binding of these idiotype-specific substances to B cell sIg is required, 
presumably, for their suppressive effects, the loss of sIgD might interfere with their 
binding and, thus, enhance antigen-specific antibody responses. However, this model 
requires that sIgM, which is still present in large amounts on most B cells after the 
4.22aM~ injection, is not able to bind idiotype-specific suppressor substances and/or 
is not  able to transmit  a  suppressive signal  to the same degree as sIgD or as sIgM 
together with sIgD. 
A  third model proposes that  the binding of anti-~-chain antibody (or antigen)  to 
sIgD partially activates B lymphocytes. This partial activation would be insufficient FINKELMAN ET AL.  503 
to induce terminal differentiation, but might make the B cell respond more readily to 
T  cell helper factors or other stimulators of B cell terminal differentiation. Several 
lines of evidence suggest that anti-8-chain antibody may partially activate B lympho- 
cytes. First, although 4.22aM~' does not induce B lymphocyte proliferation in vitro, 
both affinity-purified RaM8 and goat anti-mouse 8-chain antibody cause in vitro B 
lymphocyte proliferation (31). Second, treatment of murine B lymphocytes in vivo or 
in vitro with monoclonal or affinity purified anti-8-chain antibody causes these cells 
to  express  considerably  more  I-region  associated  (Ia)  determinants  on  their  cell 
surfaces as detected by immunofluorescence using a FACS (32). This phenomenon is 
of particular interest because Ia appears to play a role in the interaction of B ceils, T 
cells, and macrophages and could be a  receptor for T  helper factors (33, 34). Third, 
Parker et al. have found that 4.22aM~  (or RAM#) bound to polyacrylamide beads 
greatly enhances  concanavalin  A  helper-factor-induced  in  vitro  differentiation of 
murine B lymphocytes into Ig-secreting cells ([35];  and D. Parker. Personal commu- 
nication.). 
The concept that anti-8-chain antibody partially activates B lymphocytes fits well 
with  the  observation  that  4.22aM~  enhancement  of humoral  immune  responses 
requires the presence of both T  lymphocytes and considerable doses of antigen. Both 
antigen and T  lymphocytes would be necessary for the generation of carrier- and/or 
idiotype-specific T  helper factors that are required to induce terminal differentiation 
of the partially activated B lymphocytes. The lack of 4.22aM~ enhancement of the 
antibody response to suboptimal antigen doses leads us to hypothesize that fairly high 
levels of T  help are required to produce this enhancement and that such amounts of 
T  help are produced only when high quantities of antigen are used. Alternatively, 
large antigen doses may be required for optimal focusing of antigen-specific helper 
factors onto B cells that have lost slgD (i.e., helper factors may bind to antigen that 
has itself bound to B  lymphocyte surface Ig, or antigen may itself be incorporated 
into  helper  factor).  Reports  that  some  anti-g-chain  antibodies  block  the  in  vitro 
antibody response to TNP-Ficoll and SRBC (36, 37) might raise the possibility that 
T  cell  help  is  limiting  in  these  in  vitro  systems,  and  suggest  that,  under  these 
circumstances, partial activation of B lymphocytes by anti-g-chain antibody might 
actually suppress  terminal  differentiation. According to  this  concept,  anti-g-chain 
antibody mimics the effect of large antigen doses, which can suppress B cell terminal 
differentiation  in  the  absence  of T  help  but  stimulate  antibody  secretion  when 
sufficient T  help is present (12, 37, 38). 
If anti-g-chain antibody enhances antigen-specific antigen responses by partially 
activating B lymphocytes, as suggested by our third model, it can be questioned why 
partial  activation  is  not  achieved to  the same extent  by antigen alone as  by  the 
combination of antigen and anti-g-chain antibody, because both bind to slgD. One 
possibility  is  that  the  combination  of anti-g-chain  antibody  plus  antigen  might 
enhance the partial activation of B cells induced by antigen alone simply by increasing 
the quantity of ligand bound to B cell slg. However, the observation that 25 #g of 
4.22aMb  ~ enhances the IgG anti-TNP response to a large dose of TNP-SRBC as well 
as 800 #g of this antibody does not support this hypothesis, because more slgD will be 
bound by 800 #g of anti-g-chain antibody then by 25 #g. 
A  second  possibility  is  that  anti-g-chain  antibody  enhances  the  B  cell  partial 
activation produced by antigen alone by increasing the ratio of sIgD:sIgM bound by 504  ANTI-&CHAIN-ANTIBODY-ENHANCED  MURINE ANTIBODY SECRETION 
ligand. We find this hypothesis attractive as it is consistant with observations that the 
binding of ligand to sIgM is more tolerogenic to a cell than the binding of the same 
ligand to sIgD (39-41). 
Summary 
Heterologous anti-8-chain antibodies  have an  adjuvant  effect on specific in  vivo 
humoral immune responses to simultaneously, or subsequently, injected antigens in 
the rat and rhesus monkey. We have used a hybridoma-secreted antibody that binds 
murine 8-chain of the a allotype (4.22aM~)  to study this phenomenon in the mouse 
and to investigate the mechanism of this effect. Injection of 4.22aM~ into BALB/c 
mice removes almost all surface IgD (sIgD)  from splenic B  lymphocytes, slgD does 
not  reappear  until  the  serum  level  of 4.22aM~  decreases  5-7  d  after  injection. 
4.22aM~  fails  to  induce  detectable  proliferation  or  to  raise  total  serum  Ig  levels 
substantially  above control values.  However, 4.22aM~ injected 24 h  before antigen 
elicits  an  approximately  twofold enhancement  of serum  IgM  and  a  3-  to  10-fold 
enhancement  of serum  IgG  anti-trinitrophenyl  (TNP)  antibodies  in  response  to 
immunization with optimal doses of TNP-Ficoll or TNP-sheep red blood cells  (TNP- 
SRBC).  4.22aM~  injected  1 wk before or  3  d  after TNP-SRBC, however, has  no 
effect  on  IgG anti-TNP  levels.  The  adjuvant  effect  of anti-8-chain  antibody  was 
markedly decreased when suboptimal antigen doses were used. Furthermore, even in 
the case of TNP-Ficoll, a relatively T-independent antigen, the ability of 4.22aM8  * to 
enhance the  anti-TNP  antibody response  was T  cell  dependent.  Our data  suggest 
that  the  binding  of anti-8-chain  antibody  to  cell  sIgD  may  partially  activate  B 
lymphocytes and make them more capable of differentiating into antibody-secreting 
cells when stimulated by antigen-specific T  cell  help. 
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